^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Efficacy of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in PD-L1 Positive and/or dMMR Relapsed or Refractory Uterine/Cervical and Ovarian Carcinoma: a Phase II Trial
Excerpt:
......
Trial ID:
Source:
Title:
Long-term survival outcomes and immune checkpoint inhibitor (ICI) retreatment in patients with advanced cervical cancer who received camrelizumab plus apatinib in the CLAP study.
Published date:
05/25/2023
Excerpt:
In this single-arm phase 2 trial, 45 patients received camrelizumab (200 mg intravenously, q2w) and apatinib (250 mg orally, qd)....Age > 50, programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1, CPS ≥ 10, TMB-high, and PIK3CA mutation were associated with longer OS….This long-term follow-up data demonstrate sustained and durable efficacy of camrelizumab plus apatinib, with no new safety signals, in patients with advanced cervical cancer who progressed after prior platinum-based chemotherapy.
DOI:
10.1200/JCO.2023.41.16_suppl.e17513
Trial ID:
Source:
Title:
Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
Published date:
05/13/2020
Excerpt:
PFS was longer in patients with PD-L1-positive tumors than patients with PD-L1-negative tumors (median PFS: 9.6 versus 5.3 months; log-rank test, P = 0.017).
DOI:
10.1200/JCO.2020.38.15_suppl.6021
Trial ID:
